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ABSTRACT 
Background and Purpose: Pediatric cancers affect over ten thousand children in the 
United States each year. Although survival rates continue to climb, debilitating long-term 
side effects from cancer treatment are surfacing. The purpose of this study was to 
investigate the effects of chemotherapy on selected gait characteristics in children ages 
five to twenty-two. 
Methods: This was a prospective, cross-sectional study that investigated the differences 
found in and between children undergoing cancer treatment for non-central nervous 
system cancers and children without cancer. The data was collected in the oncology 
program of the two campuses of Children’s Hospitals and Clinics of Minnesota. Sixty 
children with cancer and thirty-six children without cancer (controls) participated in this 
study. Each participant completed impairment testing including: ankle range of motion, 
ankle strength, and neuropathy rating using the ped-mTNS. Their gait pattern was 
recorded using the GaitRite Gait Analysis System and then each subject completed a 6 
minute walk test. 
Results: Using MANOVA procedures, we found that subjects with cancer demonstrated 
significantly slower walking velocity, decreased cadence, and shorter step length (α≤.05) 
compared to controls. No significant gait differences were found between cancer patients 
who received vincristine and those who received IT methotrexate in addition to 
vincristine (α≥.05). Within the cancer group, significant correlations were found between 
underlying impairments of ankle dorsiflexion strength, and neuropathy with 
selected gait characteristics (α≤.05).  Significant correlations were also found between 
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the distance walked in six minutes with velocity and step length (α≤.05). 
Conclusions: Children who received chemotherapy treatment had significantly slower 
velocities, decreased cadence and shorter step lengths when compared to controls. 
However, adding IT methotrexate in addition to vincristine did not significantly impact 
gait characteristics. Underlying impairments, such as ankle strength, significantly 
affected gait characteristics. Finally, the distance children with cancer walked in six 
minutes was negatively impacted by their decreased velocity and step length. Overall, 
this study gives insight into the debilitating effects chemotherapy has on selected gait 
characteristics. Physical therapy may benefit this population by working to improve gait 
patterns and overall function. 
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Chapter I: INTRODUCTION 
Pediatric cancers, although rare, still affect over ten thousand children in the 
United States each year. Healthcare has extensively progressed and survival rates 
continue to improve, but cancer is still the second leading cause of death in children 
under the age of fifteen.
1
 Today, children that become cancer survivors exceed 80% of 
the pediatric cancer population. These children will very likely become long-term 
survivors and will have to learn to live with the inevitable side effects following 
treatment.
2
 
Although chemotherapeutic drugs have been successful in treating pediatric 
cancers and an increase in cure rates has been seen, the side effects of treatment may be 
extensive and debilitating.
3,4
   Many body systems are adversely affected by such drugs, 
including the cardiovascular, pulmonary and sensory systems.  
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Chapter II: REVIEW OF RELEVANT RESEARCH   
Chemotherapeutic Agent Side Effects: 
Chemotherapeutic drugs are designed to destroy rapidly dividing cells; however, 
at this time these drugs are not specific enough to target only cancerous cells. 
Unfortunately, other healthy cells in the body that also divide rapidly are affected as well. 
For example, healthy rapidly dividing cells are found in the endothelial layer of the 
gastrointestinal tract, in the blood, and in lymph nodes. Chemotherapeutic agents involve 
adverse gastrointestinal effects, immunity suppression, and low production of red and 
white blood cells and platelets. 
Although neurons in the peripheral nervous system are not rapidly dividing cells, 
they can be negatively affected by chemotherapeutic drugs. Sensory and autonomic 
neurons and the cells that support them are nourished by highly permeable capillaries that 
allow for easy diffusion of toxins.
5
 Chemotherapy drugs alter axonal transport and also 
hinder the metabolic needs of neurons, thus leading to impaired motor and sensory 
function.
5
 
Two such drugs utilized in chemotherapy for the treatment of common childhood 
cancers are methotrexate (MTX) and vincristine(VCR). MTX is widely used to treat 
leukemias and solid tumors in children, and is known to lead to neurotoxicity of the 
central nervous system when administered intrathecally or in conjunction with radiation 
therapy.
5
  The side effects of central neurotoxicity may also have a part in contributing to 
overall neurotoxicity.
6
  VCR in conjunction with other agents has been effective in 
treating many children with cancer in the United States.
7
  However, this treatment has 
3 
 
 
 
multiple toxic side effects which limit the dosage at which it can be administered. These 
effects often present as peripheral neuropathy, with progressive involvement of motor, 
sensory, and autonomic systems.
7
  The symptoms that accompany the neurotoxic side 
effects are pain, numbness and tingling of the hands and feet, and weakness in both upper 
and lower extremities.
8,5  
Within the first five months of treatment, children are at risk of 
developing weakness and experiencing a decrease in functional mobility.
6
 Other long 
term impairments include slowed motor nerve conduction velocity, diminished or absent 
deep tendon reflexes, decreased ankle range of motion, further weakness in distal 
musculature, which have a negative impact on functional mobility.
9,5
 
To date, there are studies that demonstrate that children treated with VCR and 
MXT perform significantly poorer on functional outcome measures for playing activities 
and mobility when compared to healthy children.
10
 Research has also indicated decreased 
walking efficiency in adult survivors of pediatric cancer.
9
 However, the impact of 
neurotoxic chemotherapy on neuromuscular gait characteristics in children and 
adolescents undergoing treatment has yet to be described. 
  
Gait Analysis in Children: 
There has been a variety of research, as described above, regarding the effects of 
chemotherapy on many different aspects of function. However, limited research has been 
conducted connecting these effects to changes in pediatric gait patterns. There are a 
variety of techniques used to measure temporal and spatial gait characteristics that have 
the potential to change with chemotherapy treatment. 
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Visual observation and video analysis with a stopwatch are two inexpensive 
techniques to measure gait characteristics with moderate to high reliability, but only 
determine temporal gait characteristics. Paper walkway is a technique used to measure 
temporal characteristics through visual observation and some aspects of spatial 
characteristics from footprints on the paper. Although this method can be used to measure 
both temporal and spatial aspects of gait, it can be time consuming to set up and analyze 
data. In more recent years, the GaitRite system was developed as a simplified data 
collection system for temporal and spatial gait analysis. This system uses a flat walkway 
with multiple pressure sensors, which record a variety of gait characteristics on a 
computer. Several research studies have focused on determining the validity and 
reliability of the GaitRite system with a wide variety of subjects ranging from children to 
adults and healthy to impaired subjects. Overall, high validity and reliability have been 
established for this system.
11,12
 
The GaitRite system has also been utilized to analyze pediatric and adult gait 
patterns in populations that present with impaired gait. These studies obtained normative 
and impaired temporal-spatial gait characteristics in children, young adults, and adults 
using the GaitRite walkway system, which has been reported to have moderate to high 
validity and reliability. The data obtained is able to be utilized as a comparison for future 
studies and is beneficial in recognizing pathologic gait characteristics.
13,14,15,16
  For these 
reasons the GaitRite system was chosen for gait data collection of the present study.  
The purpose of this study was to investigate the effects of chemotherapy on 
selected gait characteristics in children and adolescents ages five to twenty-two years.  
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This study is part of a larger, on-going study of the impact of chemotherapy on physical 
function in school-aged children and adolescents. 
We generated multiple hypotheses based on the available literature for this study: 
1.   The gait characteristics of children/adolescents with cancer will differ from   
children/adolescents without cancer. 
2.   The gait characteristics of subjects treated with different types of chemotherapy (that 
is vincristine vs. vincristine with MTX) will be similar.  
3.   Select neuromuscular impairments will be significantly related to changes observed in 
the gait pattern of children/adolescents with cancer. 
4.   Children/adolescents without cancer will walk farther in six minutes compared to 
children/adolescents with cancer.   
5.   Selected gait characteristics will be significantly related to the distance subjects 
walked in six minutes. 
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Chapter III: METHODS 
Study Design 
The study had a prospective and cross-sectional design that used a descriptive 
technique to analyze gait characteristics and is quasi-experimental in estimating the 
impacts of chemotherapy on selected gait characteristics. All the data collected for each 
participant was completed in one day and included a chart review or health history and 
impairment, gait, and functional measurements. 
 
Subjects 
Participants were recruited through the oncology program at the two campuses of 
the Children’s Hospitals and Clinics of Minnesota. Subjects and their parents were 
approached in either the hospital or outpatient clinic during a routine visit.  One of the 
investigators invited the subjects and any siblings meeting the criteria to participate. After 
recruitment, the patient population included sixty children, between the ages of five and 
twenty-two, who fit within the inclusion and exclusion criteria. The inclusion criteria 
included having a diagnosis of either ALL, a type of lymphoma, or a solid tumor; at the 
appropriate point in treatment based on diagnosis and treatment regime (see appendix A); 
subjects who gave assent according to institutional guidelines and parental consent to 
participate. Exclusion criteria included a diagnosis of CNS cancer; a lower extremity 
amputation or limb salvage surgery; an antecedent neurological, developmental, or 
genetic disorder; or an ICU stay longer than 48 hours in the previous two weeks. The 
control population included thirty-six children, between the ages of five and twenty-one, 
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who were siblings of the patient population or children of clinical staff at Children’s 
Hospitals and Clinics of Minnesota. After completing all the testing, each participant 
received a ten-dollar gift card. 
  
Procedures 
Initially, general health information was collected through a chart review for the 
patient population and a health history form for the control population. The information 
gathered from both groups included the following: age, gender, height, weight, leg 
length, co-morbid conditions, and current medications. Additionally, cancer type and 
treatment parameters were collected by medical record abstraction for the patient 
population. 
Impairment measures included a neuropathy scale and ankle dorsiflexion range of 
motion (ROM) and strength. These impairments were chosen based on previous 
literature, which states these impairments have impacts on the functional mobility of 
individuals after chemotherapy treatment. 
5,6,9
 The neuropathy scale used was the 
pediatric-modified total neuropathy scale (ped-mTNS), which is a scale adapted by Dr. 
Laura Gilchrist for the use in the pediatric population. This scale uses clinical assessment 
tools including deep tendon reflexes, pin sensibility, vibration sensation, light touch, and 
manual muscle testing.
20,21
  Based on the score in all five areas, an overall score is 
generated. (see appendix B) 
Ankle dorsiflexion ROM was measured with subject positioned in prone with the 
knee extended and the foot over the edge of the table. The knee extended position has 
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been found to correlate best with available ROM of the ankle during heel strike phase of 
gait (a point in the gait cycle that the greatest amount of ankle dorsiflexion is required). 
When a standardized approach is used by trained clinicians, the inter-rater reliability has 
been reported to be high (0.88).
22
  The last impairment measure was ankle dorsiflexion 
strength, which was measured in standard manual muscle testing position.  Reliability for 
manual muscle testing has been reported to be good (0.63).
23
 
  The GaitRITE gait analysis system was used to collect the gait measures used in 
this study. This system involves an electronic walkway that contains sensor pads that are 
connected to a computer for data acquisition. The spatiotemporal parameters of gait 
focused on in this study included velocity, cadence, step length, single limb support, 
double limb support, and base of support. The GaitRITE was used instead of 
observational gait analysis since the GaitRITE has been proved to be reliable and valid 
among a multitude of populations as discussed earlier, whereas; observational gait 
analysis has questionable validity and reliability.
24,25
 Each subject completed two trials 
and the gait variables were averaged for the two trials. All subjects were instructed to 
walk at their “normal” speed.  Additionally, velocity, cadence, and step length were 
normalized to account for the varying height differences amongst the participants.  
Lastly, the functional measure used was the six minutes walk test (6MWT), which  
is a measure of sub-maximal functional capacity and endurance of the cardiorespiratory 
system. Guidelines for administration from American Thoracic Society
26
 were followed. 
The 6MWT demonstrated strong concurrent validity to the VO2 max during the treadmill 
test and strong test-retest reliability.
27
 Recently, height-specific reference standards for 
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the 6MWT were constructed using a sample of 1,445 healthy children aged 7 to 16 
years.
28
 
 
Statistical Analysis 
 After the data collection, the data was entered into an Excel spreadsheet by two 
researchers.  Two different researchers performed a spot check of the data to ensure 
accurate entry and removed extreme values determined to be likely due to measurement 
error and subjects with missing data. 
 In order to account for unequal stature between participants, various methods of 
normalization that have been previously established in other studies was investigated. 
These methods include scaling data to leg length, height, velocity, and body mass.
29
 In 
literature, Hof discussed non-dimensional forms as methods of normalizing data such as 
by leg length. Hof described dividing data by the normalization variable or using ratios to 
obtain dimensionless data.
29
 In addition, a study by Standsfield et al. reported semi-
dimensional and non-dimensional normalized data in a seven year longitudinal study of 
gait in 16 children ages 5-12 years old.  In this study, the children walked over the 
GaitRite system and the researchers collected ground reaction forces, motion data, 
weight, height and leg length. Semi-dimensional normalization was used for velocity, 
cadence, and step length based on description in the literature. Non-dimensional 
normalization was utilized for weight, length and time. The gait data was normalized to 
height and leg length. These authors recommended use of non-dimensional normalization 
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rather than semi-dimensional for comparing the development of children’s gait 
patterns.
18,29
 
 Based on the literature stated above, selected gait characteristics including 
velocity, cadence, and left and right step length were normalized in order to account for 
size differences amongst participants per the protocol described by Strandsfield et al. The 
formula used for normalization was (leg length/height) x variable, where the variable was 
either velocity, cadence, or step length.
18
 Stride length was not analyzed for our purposes 
as it is not directly addressed in clinic practice. 
 SPSS version 19 was used for statistical analysis of the results. ANOVA and 
MANOVA procedures were used to analyze variance between groups. MANOVA was 
used when multiple variables were included in the analysis in order to minimize 
experiment-wise error rate. Pearson R correlation was used to verify relationships 
between selected variables. 
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Chapter IV: RESULTS 
Demographics 
         Table 1 shows the means +/- 1 standard deviation of age and height and 
percentage for gender and cancer type as well as the percentages for gender and cancer 
type. Based on the MANOVA analysis, no statistical significance difference was found 
between the two groups ( >0.05). A MANOVA analysis revealed that there was no 
significant difference in age, height, and gender between the cancer and control group. 
Table 1. Baseline characteristics of patients with cancer and the control group 
 Cancer Group (n=60) 
Mean ± 1 SD 
Control Group (n=36) 
Mean ± 1 SD 
Age (years) 11.6 ± 4.6 11.2 ± 3.4 
Height (cm) 147.4 ± 23.2 149.3 ± 18.7 
Gender  (%M) 43 53 
Diagnosis (%) 48.3 
ALL 
30.0 
Lymph 
21.7 
ST 
NA 
 
 Our first hypothesis was that the gait characteristics of children/adolescents with 
cancer will differ from children/adolescents without cancer.  A MANOVA  analysis 
using Wilks' Lambda between the cancer (n=60) and the control group (n=36) was run to 
determine differences between the groups for the following gait characteristics: mean 
normalized velocity, cadence, left and right step length, and right and left base of support, 
and single limb support time.  The analysis revealed significant differences between the 
cancer and control group for mean normalized velocity, cadence and left step length 
(p≤.05).  Subjects with cancer demonstrated significantly slower walking velocity 
(p=.001), decreased cadence (p=.007) and shorter left step length (p=.034) compared to 
controls. Mean normalized right step length approached significance at p=.056, however, 
12 
 
 
 
was not statistically significant.   In addition, there was no significant difference in mean 
left and right base of support and single limb support time between the groups (p≥.05).  
This analysis yielded sufficient power at 0.860. 
 
Graph 1 and 2 show the significant differences in mean normalized velocity and cadence 
between the cancer and control group (p≤0.05).  These graphs demonstrate that subjects 
with cancer had significantly reduced velocity and cadence. 
 
 
 
 
 
Graph 3 shows differences in mean 
normalized left and right step length 
between the cancer and control group.  
Left step length was found to be 
significantly different between the 
groups (p ≤0.05) and although right step 
length approached significance at 0.056, 
it was not significant.  
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Our second hypothesis was that the gait characteristics of children treated with 
different types of chemotherapy regimes will be similar. A MANOVA analysis using 
Wilks' Lambda between subjects who received only vincristine (n=22) and those who 
received vincristine with intrathecal (IT) methotrexate (n=38) was run to determine 
differences between the chemotherapy treatment groups for the following selected gait 
characteristics: mean normalized velocity, cadence, left and right step length, and right 
and left base of support, and single limb support time.  The MANOVA analysis showed 
that no significant differences were found in gait characteristics when adding IT 
methotrexate to vincristine treatment for normalized velocity, cadence, left and right step 
length, and  left and right base of support and single limb support time (Wilks' 
Lambda=.932; F8-51=.467;p=.873).  The power analyses yielded a power of 0.195 
suggesting that there was an  insufficient sample size to detect a  difference between 
groups.  
Graphs 4 and 5  illustrates the effect of Vincristine and Vincristine with IT Methotrexate 
on the mean normalized velocity and cadence in patients with cancer. These graphs show 
that no significant differences were found between treatments for these gait variables 
(p≥0.05). 
14 
 
 
 
 
Graph 6 illustrates the effect of 
Vincristine and Vincristine with IT 
Methotrexate on the mean normalized 
left step length. Similarly, there was no 
difference in left step length between 
the chemotherapy treatment groups 
(p≥0.05). 
 
 
 
 
  Our third hypothesis was that select neuromuscular impairments will be 
significantly related to changes observed in the gait pattern of children with cancer. The 
Pearson R correlation analysis was used to determine relationships between impairment 
and gait variables. Explored impairment variables included neuropathy, left and right 
dorsiflexion strength, and left and right active dorsiflexion range of motion. Explored gait 
variables included normalized velocity, cadence, and left and right step length.  Other gait 
variables such as right and left base of support and single limb support were not included 
in the correlation analysis as they were not statistically significant between the cancer and 
control groups.  Mean normalized cadence was significantly inversely correlated with 
mean neuropathy (r= -.280, p ≤.05). Also, mean left dorsiflexion strength was positively 
correlated with mean normalized left step length (r=.306, p ≤.05). Lastly, mean right 
dorsiflexion strength was significantly positively related to normalized mean right step 
length (r=.263, p ≤.05).  Based on the correlation analysis we found that patients with 
higher neuropathy scores demonstrated lower cadence. In addition, patients with greater 
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left and right dorsiflexion strength had longer left step length.  No other correlations 
between neuromuscular impairments and gait characteristics were statistically significant. 
 
Table 2. Significant Correlations Between Impairments and Gait Characteristics 
Gait Variables Impairments 
 Neuropathy  L DF 
Strength 
R DF 
Strength 
L DF 
ROM 
R DF 
ROM 
Velocity -.100 .217 .209 .069 .058 
Cadence -.280* -.055 -.040 .159 .176 
L Step Length .111 .306* .263* -.084 -.093 
R Step Length  .149 .246 .218 -.052 -.036 
Table 2 demonstrates the significant correlations between impairments and gait 
characteristics.  The correlation (r) value is listed between impairment variables and gait 
variables.  Significant correlations are bolded in the table. * Indicates significance of     
p≤ 0.05.  
  
Our fourth hypothesis was that children without cancer will walk farther in six 
minutes compared to children with cancer. An ANOVA analysis using Wilks' Lambda 
between the cancer (n=60) and the control group (n=36) was run to determine if a 
difference existed in the 6 minute walk distance between the groups. The 6 minute walk 
distance was chosen for analysis as it is a functional measure of the efficiency of ones' 
gait. The analysis revealed significant differences in the distance children were able to 
walk in 6 minutes between children with cancer compared to controls (p≤.001). Our 
results suggest that patients without cancer walker farther in 6 minutes when compared to 
children with cancer. 
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Graph 7 demonstrates the 6 minute walk 
distance in meters between the cancer and 
control group.  This graph demonstrates 
that patients without cancer walked 
farther in 6 minutes when compare to 
children with cancer (p≤0.05). 
 
 
 
 
Our fifth hypothesis was that selected gait characteristics will be significantly 
related to the distance cancer patients walked in six minutes. Pearson R analysis was used 
to determine relationships between gait characteristics and the 6 minute walk distance. 
Variables that were included in Pearson R analysis were the 6 minute walk distance, left 
and right single limb support and normalized velocity, cadence, and left and right step 
length. Significant positive correlations were found between the distance walked in 6 
minutes and normalized velocity and step length in cancer patients. Mean normalized 
velocity was positively correlated with mean 6 minute walk distance (r=.354, p≤.05). 
Mean normalized right step length demonstrated a positive relationship with mean 6 
minute walk distance (r=.347, ,p≤.05). Lastly, mean normalized left step length 
demonstrated a positive relationship with mean 6 minute walk distance (r=.321,  p≤.05). 
No other significant correlations were found. These results suggest that with increased 
speed and step length (right greater than left), children demonstrated increased walking 
17 
 
 
 
distance in 6 minutes. In addition, we did not find a significant relationship between 
single limb support, and normalized cadence with 6 minute walk distance. 
 
Table 3. Significant correlations between selected gait variables and 
6 minute walk distance 
 Significant Correlation Values 
Normalized Velocity  .354* 
Normalized R Step Length .347* 
Normalized L Step Length .321* 
Table 3 demonstrates significant correlations between selected gait variables and the 6 
Minute Walk Distance( p ≤0.05).  
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Chapter V: DISCUSSION  
The results of the current study indicate children who have gone through a 
chemotherapy treatment of vincristine or vincristine with IT methotrexate have impaired 
gait characteristics and functional mobility compared to children without cancer.  
Significant differences were found both at the impairment and functional levels, with 
significant correlations between the two.  Children treated with chemotherapy had 
significantly slower velocities, decreased cadence and left step length when compared to 
the control group, suggesting that chemotherapy has a negative impact on gait 
characteristics.   
Although differences between the groups were found, no significant results were 
found as a function of the type of chemotherapy received within the cancer group.  The 
addition of IT methotrexate to the vincristine regimen did not significantly affect any of 
the children’s gait characteristics.   These results are somewhat consistent with what 
Hartman and colleagues found in 2006
8
 when investigating the motor performance in 
children with cancer and whether this performance was based on cumulative vincristine 
dosage.  Using the Movement Assessment Battery for Children scale (m-ABC), they 
measured differences in 128 children between ages of 4 and 12 who had completed 
treatment at least one year prior.  Results of that study found no significant differences on 
the functional measures between children who received pulses of vincristine and steroids 
during treatment compared to those who did not.  This literature, in addition to our 
results, suggests the addition of IT methotrexate does not further influence the effect on 
gait characteristics.          
19 
 
 
 
Investigation into the impact of impairments on gait characteristics in this study 
revealed significant associations within the cancer group.  As hypothesized, worse 
neuropathy was associated with a reduced cadence, as well as stronger left and right 
dorsiflexion strength correlated with increased left step length.  Comparison of these 
results to previous literature found changes in ankle dorsiflexion and peripheral muscle 
strength as long-term side effects of chemotherapy treatment in children.  A study done 
by Hartman and colleagues
10
 examined these deficiencies in ankle dorsiflexor and wrist 
extensor strength and ROM pinch grip, as well as their association with motor 
performance. When comparing these impairments to functional measures, ankle 
dorsiflexion ROM was not significantly correlated with functional movement on the m-
ABC.  Although this study investigated functional movement and not specific gait 
characteristics, it was similar to our findings of a lack of correlation between ankle ROM 
and gait characteristics.          
Another result of this study found children without cancer walked farther 
distances in six minutes than those in the cancer group.  This was consistent with what 
we anticipated and is congruent with the literature Ness and colleagues
9
 performed that 
found walking efficiency was the most common physical performance limitation seen in 
cancer survivors, with 46.5% of participants scoring in the lowest 10th percentile, 
compared to age, sex, height, and weight matched normative values.  While in this 
analysis we did not normalize the data for height or gender, the demographic analysis of 
the two groups yielded no significant differences.  Thus, we feel comfortable that the 
differences between groups on the six minute walk distance are due to cancer and 
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treatment variables and not height or gender.  Overall, these findings demonstrate the 
negative impact cancer and chemotherapy have on functional activities such as 
community ambulation.  
          Our final hypothesis studied the impact of gait characteristics on the six-minute 
walk test results.  Consistent with our prediction, we found that six minute walk distance 
was significantly correlated with self-selected “normal” velocity on the GaitRite mat as 
well as left and right normalized step lengths for their “normal” walking velocity.  Ankle 
dorsiflexion strength was positively correlated with step length and step length was also 
positively correlated with velocity.  These relationships suggest variables such as these 
can impact the ability to walk efficiently.  It is important to take into consideration, 
however, the toxicity chemotherapy has on other systems, such as the cardiovascular and 
pulmonary systems, which also affect the distance one can walk in six minutes. The 
analysis of the impact of impairments of other body structures and systems on walking 
distance is beyond the scope of this study. 
Collectively, these outcomes uncover the potential for physical therapy in this 
population and suggest therapists should take into consideration the power of improving 
ankle dorsiflexion strength and delegating time to perform gait interventions.  It is also 
important for therapists to examine the barriers to treating this population. A study by 
Jones and colleagues
19
 found the barriers for exercise recommendations by physicians 
included not being aware of the benefit in this population and being unsure of referral 
options. It is crucial that therapists strive to educate physicians on the available literature 
21 
 
 
 
and potential for physical therapy as well as provide a referral option for cancer 
survivors. 
The results from this study should be interpreted while taking into consideration 
possible limitations. These include a limited number of participants and diagnoses as well 
as no intentional age or gender matching between groups at this time.  The impairments 
and gait characteristics were only measured once, compared to examining the changes 
over time.  The impact of the two agents vincristine and IT methotrexate were analyzed; 
however, children did receive other medications that could potentially impact gait 
variables.  The GaitRite system was used to measure the gait characteristics and therefore 
there was no kinematic record or EMG data to examine.  All of these limitations have to 
potential to be addressed in follow up studies of this population.  
There are many future opportunities for research on this topic.  It would be 
beneficial to measure the changes in gait characteristics before and after performing the 
six-minute walk test in order to evaluate the impact of fatigue on these parameters.  It 
would also be important to recruit more participants, match the control and cancer group 
by age and gender and further evaluate the impact of differing chemotherapy doses of 
vincristine and IT methotrexate as well as the influence of other medications.  It would be 
valuable to track changes in impairments over time and research needs to be conducted to 
investigate the impact physical therapy interventions may have on improving gait 
characteristics in this population. 
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Chapter VI: CONCLUSION 
In conclusion, this study gives insight into the impact of chemotherapy on 
selected gait characteristics in children and young adults.  Physical therapy may benefit 
this population by working to improve impairments, gait patterns, and overall function. 
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APPENDICES 
Appendix A: Timing of Measurement        
*  Indicates Time of Physical Impairment and Motor Performance Measurement 
Diagnosis Month   1 2 3 4 5 6 7 8 9 10 11 12 
ALL    Intensive Chemotherapy                                                                  * Maintenance Chemo  2-3 years 
Lymphoma  
Hodgkins 
Low Risk 
 Chemotherapy                             * 
 
Follow-up 
Hodgkins 
Int/High Risk 
 Chemotherapy                                 * Follow-up 
Non-Hodgkins   Chemotherapy                             * Maintenance Chemo Follow-up 
Solid Tumors  
Ewings Sarcoma  Chemotherapy S ± 
R 
Chemotherapy               *       Follow-up 
EwingsSarcoma 
/alt protocol 
 Chemotherapy S ± 
R 
Chemotherapy                * Follow-up 
Neuroblastoma 
 
  Chemotherapy (up to 1 year)                                                                * (or within 1 month of end if treatment > 6 mo) 
Rhabdomyo-
sarcoma Low risk 
Chemotherapy S± 
R 
Chemotherapy                                             * Follow-up 
Rhabdomyo-
sarcoma Int. Risk 
Chemo S ± 
R 
Chemotherapy                                                         * Follow-up 
Wilm’s  
Tumor 
S± 
R 
Chemotherapy                                                                                 *                                                                       Follow-
up 
Wilm’s  Tumor 
Alt. Protocol 
Chemotherapy S± 
R 
   Chemotherapy                * Follow-up 
 S = Surgery, R = Radiation 
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Appendix B: 
Pediatric - Modified Total Neuropathy Scale 
 
Sensory Symptoms: ______ (record worst score for the three sensations) 
“ Do you have any parts of your body that are tingly, numb (can hardly feel), or hurt?”  
______ Tingly ______ Numb  ______ Hurt    (record number for each) 
If yes, “Where you have those feelings?”   
0 None 
1 Symptoms limited to fingers or toes 
2 Symptoms extend to ankles or wrists 
3 Symptoms extend to knee or elbow 
4 Symptoms above knee or elbow 
 
Functional Symptoms:  ______ (record worst score of the three questions) 
“Do you have trouble buttoning shirts or tying your shoes?” ______  
“Do you have trouble walking such as tripping frequently?” ________  
“Do you have trouble going up or down stairs?” _______  
           If yes to any, “Is it…..(read choices)” and record after each question 
0 Not Difficult 
1 A little difficult 
2 Somewhat difficulty 
3 I need help 
4 I can’t do that at all 
 
Autonomic Symptoms: _____ (record worst score of the three questions) 
 “Do you feel dizzy or light-headed when you get up out of bed?” 
 “Do your hands or feet feel hotter or colder than normal?” 
0 Never 
1 A little bit 
2 Sometimes 
3 Very much 
4 Almost always 
Clinical Testing: 
Light Touch Sensation:  ______   
0 Normal 
1 Reduced in fingers/toes 
2 Reduced up to wrist/ankle 
3 Reduced up to elbow/knee 
4 Reduce to above elbow/knee 
 
 
 
 
 
 
 
 
 Semmes  Semmes Bumps 
Toes        R  Finger  R   
                L               L   
Med Mal R  Wrist    R  XXX 
                L               L  XXX 
Knee        R  Elb       R  XXX 
                L               L  XXX 
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Pin Sensibility: _____ 
0 Normal 
1 Reduced in fingers/toes 
2 Reduced up to wrist/ankle 
3 Reduced up to elbow/knee 
4 Reduce to above elbow/knee 
 
 
Vibration Sensibility: _______ (worst score)  
0 Normal  
1 Reduced in fingers/toes   
2 Reduced up to wrist/ankle    
3 Reduced up to elbow/knee    
4 Reduce to above elbow/knee   
 
 
 
 
 
 
 
 
 
 
Strength: _____ Worst Score    (MRC Score R / L)       
    MRC level: Great Toe ___/___ ankle DF___/___  finger abd___/___  wrist ext___/___   
0 Normal 
1 Mild weakness (MRC 4) 
2 Moderate weakness (MRC 3) 
3 Severe weakness (MRC 2) 
4 Paralysis (MRC 1-0) 
 
 
Deep Tendon Reflexes: _____    (Achilles, Patellar)     
0 Normal 
1 Ankle reflex reduced  (Achilles +1) 
2 Ankle reflex absent (Achilles 0, others +2) 
3 Ankle reflex absent, others reduced (Achilles 0, others +1) 
4 All reflexes absent (all 0) 
 
 
 Bioesth R-S TF  Bioes R-S TF 
Toes        R /  Finger  R /  
                L /               L /  
Med Mal R /  Wrist    R /  
                L /               L /  
Knee        R /  Elb       R /  
                L /               L /  
